WO1997005267A3 - Mucosal delivery of polynucleotides - Google Patents

Mucosal delivery of polynucleotides Download PDF

Info

Publication number
WO1997005267A3
WO1997005267A3 PCT/US1996/012041 US9612041W WO9705267A3 WO 1997005267 A3 WO1997005267 A3 WO 1997005267A3 US 9612041 W US9612041 W US 9612041W WO 9705267 A3 WO9705267 A3 WO 9705267A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
animal
binding protein
polynucleotides
mucosal delivery
Prior art date
Application number
PCT/US1996/012041
Other languages
French (fr)
Other versions
WO1997005267A2 (en
Inventor
Dannie H King
Original Assignee
Maxim Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharmaceuticals filed Critical Maxim Pharmaceuticals
Priority to AU65057/96A priority Critical patent/AU6505796A/en
Priority to EP96924664A priority patent/EP0840796A2/en
Priority to CA002227871A priority patent/CA2227871A1/en
Priority to JP9507664A priority patent/JPH11510164A/en
Publication of WO1997005267A2 publication Critical patent/WO1997005267A2/en
Publication of WO1997005267A3 publication Critical patent/WO1997005267A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A composition for delivery of a polynucleotide to mucosal, neural, or other cells, comprising a GN1-binding protein and a polynucleotide in association with the binding protein; and a method for modulating immunity comprising administering the composition to an animal and expressing the polynucleotide whereby the animal generates an immune response to the product of the polynucleotide; and a method for gene therapy comprising administering to an animal a GM1-binding protein and a functional polynucleotide and expressing the polynucleotide in the animal whereby the function of the polynucleotide confers on the animal a therapeutic effect.
PCT/US1996/012041 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides WO1997005267A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU65057/96A AU6505796A (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides
EP96924664A EP0840796A2 (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides
CA002227871A CA2227871A1 (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides
JP9507664A JPH11510164A (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US152795P 1995-07-26 1995-07-26
US60/001,527 1995-07-26

Publications (2)

Publication Number Publication Date
WO1997005267A2 WO1997005267A2 (en) 1997-02-13
WO1997005267A3 true WO1997005267A3 (en) 1997-04-24

Family

ID=21696500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/012041 WO1997005267A2 (en) 1995-07-26 1996-07-19 Mucosal delivery of polynucleotides

Country Status (5)

Country Link
EP (1) EP0840796A2 (en)
JP (1) JPH11510164A (en)
AU (1) AU6505796A (en)
CA (1) CA2227871A1 (en)
WO (1) WO1997005267A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6553398A (en) * 1997-03-12 1998-09-29 Hybridon, Inc. Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides
GB9713122D0 (en) * 1997-06-20 1997-08-27 Chiron Spa Novel method of DNA transfer into cells
BR9914160A (en) * 1998-09-30 2001-06-26 American Cyanamid Co Antigenic composition, method for increasing the capacity of an antigenic composition that contains an antigen selected from a pathogenic bacterium, virus, fungus or parasite, haemophilus influenzae, helicobacter pylori, respiratory syncytial virus, rotavirus, and simple virus of the herpes to evoke the immune response of a vertebrate host, plasmid, host cell, method to produce an immunogenic mutant cholera holotoxin, and use of an effective auxiliary amount of a mutant cholera holotoxin
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US7041296B1 (en) * 1999-11-12 2006-05-09 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating inflammatory bowel disease using cholera toxin B subunit
CN1541111A (en) 2001-06-07 2004-10-27 ���Ͽع����޹�˾ Mutant forms of cholera holotoxin as adjuvant
EP1404368B1 (en) 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
CN101143221A (en) * 2002-03-15 2008-03-19 布赖汉姆妇女医院 Central airway administration for systemic delivery of therapeutics
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20160104727A (en) 2014-01-16 2016-09-05 아카데미아 시니카 Compositions and methods for treatment and detection of cancers
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
KR20170005142A (en) 2014-05-27 2017-01-11 아카데미아 시니카 Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3149037A4 (en) 2014-05-27 2018-01-10 Academia Sinica Anti-her2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3149036A4 (en) 2014-05-27 2017-12-27 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
JP7063538B2 (en) 2014-05-28 2022-05-09 アカデミア シニカ Anti-TNFα sugar-manipulated antibody group and its use
TWI745275B (en) 2014-09-08 2021-11-11 中央研究院 HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006635A1 (en) * 1985-05-15 1986-11-20 Biotechnology Australia Pty. Ltd. Oral vaccines
JPS63258493A (en) * 1987-04-15 1988-10-25 Mitsui Toatsu Chem Inc Anti-ganglioside gm, monoclonal antibody, cell producing said antibody and reagent composed thereof
EP0372928A2 (en) * 1988-12-07 1990-06-13 University Of Leicester Heat-labile toxin B subunit fusion proteins
EP0418626A2 (en) * 1989-09-08 1991-03-27 Takeda Chemical Industries, Ltd. Fused proteins and production thereof
WO1991007979A1 (en) * 1989-11-29 1991-06-13 Center For Innovative Technology Chimeric proteins
WO1993019183A1 (en) * 1992-03-23 1993-09-30 University Of Massachusetts Medical Center Immunization by inoculatioon of dna transcription unit
WO1994009823A1 (en) * 1992-11-03 1994-05-11 Oravax, Inc. Urease-based vaccine against helicobacter infection
WO1994023752A1 (en) * 1993-04-16 1994-10-27 University Of Portsmouth Enterprise Limited Drug delivery system
WO1995010301A1 (en) * 1993-10-08 1995-04-20 Duotol Ab Immunological tolerance-inducing agent
US5433946A (en) * 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006635A1 (en) * 1985-05-15 1986-11-20 Biotechnology Australia Pty. Ltd. Oral vaccines
JPS63258493A (en) * 1987-04-15 1988-10-25 Mitsui Toatsu Chem Inc Anti-ganglioside gm, monoclonal antibody, cell producing said antibody and reagent composed thereof
EP0372928A2 (en) * 1988-12-07 1990-06-13 University Of Leicester Heat-labile toxin B subunit fusion proteins
EP0418626A2 (en) * 1989-09-08 1991-03-27 Takeda Chemical Industries, Ltd. Fused proteins and production thereof
WO1991007979A1 (en) * 1989-11-29 1991-06-13 Center For Innovative Technology Chimeric proteins
US5433946A (en) * 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
WO1993019183A1 (en) * 1992-03-23 1993-09-30 University Of Massachusetts Medical Center Immunization by inoculatioon of dna transcription unit
WO1994009823A1 (en) * 1992-11-03 1994-05-11 Oravax, Inc. Urease-based vaccine against helicobacter infection
WO1994023752A1 (en) * 1993-04-16 1994-10-27 University Of Portsmouth Enterprise Limited Drug delivery system
WO1995010301A1 (en) * 1993-10-08 1995-04-20 Duotol Ab Immunological tolerance-inducing agent

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE XP002027270 *
LEHNER ET AL.: "Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein", SCIENCE, vol. 258, no. 5036, 1992, pages 1365 - 1369, XP000645284 *
LYCKE ETAL.: "The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity", EUR. J. IMMUNOL., vol. 22, no. 9, September 1992 (1992-09-01), pages 2277 - 2281, XP002058448, DOI: doi:10.1002/eji.1830220915 *
NASHAR ET AL.: "Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes", VACCINE, vol. 11, no. 2, 1993, pages 235 - 240, XP000645274 *
PATENT ABSTRACTS OF JAPAN vol. 013, no. 063 (C - 568) 13 February 1989 (1989-02-13) *
PILLAI ET AL.: "Translational fusion of heat labile enterotoxin chain B and beta-subunit of human chorionic gonadotropin: periplasmic expression in Escherichiacoil and its immunogenicity", FEBS LETT., vol. 387, no. 1, 27 May 1996 (1996-05-27), pages 23 - 26, XP000645267 *
ROHRBAUGH ET AL.: "Gene transfer fior therapy and prophylaxis of HIV-1 infection", ANN. NEW YORK ACAD. SCI., vol. 685, 1993, pages 697 - 712, XP000645528 *
VAN DER HEIJDEN ET AL.: "Manipulation of intestinal immune response against ovalbumin by cholera toxin and its B subunit in mice", IMMUNOLOGY, vol. 72, no. 1, 1991, pages 89 - 93, XP000618947 *

Also Published As

Publication number Publication date
AU6505796A (en) 1997-02-26
JPH11510164A (en) 1999-09-07
EP0840796A2 (en) 1998-05-13
CA2227871A1 (en) 1997-02-13
WO1997005267A2 (en) 1997-02-13

Similar Documents

Publication Publication Date Title
WO1997005267A3 (en) Mucosal delivery of polynucleotides
EG18726A (en) 1-Nitro-2,2 diaminoethylene derivatives and their use in pest control.
AU2993297A (en) Treatment of sickle cell disease, treatment of immune system diseases and other diseases normally associated with sickle cell anemia
IL118201A0 (en) Erythropoietin free of animal proteins processes for production and use thereof
HUT69284A (en) Novel benzoyl amino acid derivs., pharmaceutical compns. conth. them and process to prepare them
EP0853121A3 (en) Human DNase
EP0681585A4 (en) Tata-binding protein associated factors, nucleic acids encoding tafs, and methods of use.
AU5229793A (en) Novel extracts of cucurbita sp., process for their preparation and use in medicaments and in cosmetics
HUP9800049A3 (en) Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
EP0147146A3 (en) Enhancement of transdermal drug delivery
IL113373A0 (en) A plant gene for resistance to vascular diseases and protein encoded thereby
AU3477295A (en) Modified proteins
WO1998007829A2 (en) Use of flexible plastic tanks in gene theraphy
EP0853486A3 (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
AU5675794A (en) Mucosal vascular addressin, dna and expression
EP0853486A4 (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
AU8239298A (en) Nucleotide-comprising composition
WO1997012963A3 (en) A paf-acetylhydrolase and use in therapy
AU6128896A (en) Isoindole derivatives, their preparation and their application in therapy
AU4904097A (en) Gene delivery and expression in areas inaccessible to direct protein delivery
WO1996004011A3 (en) Novel compound to mimic a naturally occurring peptide's effect
EP0811687A3 (en) Polypeptides having l-asparaginase activity
AU4751990A (en) Nucleotides encoding human b1, 4-galactosyltransferase and uses thereof
EP0273778A3 (en) Synergistic behavior of csf-1 and g-csf
EP0647454A3 (en) Rate responsive pacemaker with improved rate change dynamics and pacing method.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2227871

Country of ref document: CA

Ref country code: JP

Ref document number: 1997 507664

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2227871

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996924664

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996924664

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996924664

Country of ref document: EP